BlackThorn Therapeutics, Inc.

Privately held Neumora Therapeutics, Inc. has one well-funded rival in the late-stage development of a kappa opioid receptor (KOR) antagonist for the treatment of major depressive disorder (MDD), bu

Neumora Therapeutics Inc. came out of stealth mode on 7 October with more than $500m in initial financing to fund its platform for the discovery and development of precision medicines in neurological

The health care- and technology-focused venture capital firm Polaris Partners – an active investor in biopharmaceutical companies – disclosed in a filing with the US Securities and Exchange Commission

Tetraphase Pharmaceuticals Inc. took the first step toward following fellow antibiotic developer Achaogen Inc. 's troubled path, deciding recently to reorganize its business so that it can focus ent